Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

769.88 +6.92 (+0.91%)
Streaming Delayed Price Updated: 10:58 AM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Why Eli Lilly Stock Was Looking Sickly Today
It seemed the market overreacted to discouraging news from one of the company's rivals. 
Via The Motley Fool
History of Novo Nordisk A/S Stock: From Insulin Pioneers to Global Pharma Leader (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) has evolved over the past century from a humble insulin manufacturer in Denmark into one of the world’s most valuable pharmaceutical companies. With a commanding presence in... 
Via MarketMinute
Topics Economy Emissions
Lucid Signs Up Timothée Chalamet As Global Brand Ambassador: Retail Terms It A Desperate Cash-Draining Move
Chalamet will headline Lucid’s new marketing campaign for its Gravity SUV later this year. 
Via Stocktwits
Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)
In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at... 
Via MarketMinute
Topics ETFs Economy
Eli Lilly's Options Frenzy: What You Need to Know
 
Via Benzinga
Why Eli Lilly (LLY) Stock Is Falling Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the weight-loss drug market, Novo Nordisk, lowered its sales and profit growth... 
Via StockStory
Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The Stock
Jaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients treated with Jaypirca experienced their cancer shrink or disappear after... 
Via Stocktwits
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, with more data expected. 
Via Benzinga
3 Vanguard ETFs to Buy With $1,000 and Hold Forever
A few investments can expose investors to top companies from across the globe. 
Via The Motley Fool
Topics ETFs Economy
Eli Lilly Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?
Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO. 
Via Benzinga
Drug Prices To Get 'More Expensive' Under Trump's EU Trade Deal As Pharma Faces Billions In Added Costs: Report
The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted... 
Via Benzinga
Topics Government
Which S&P500 stocks are moving before the opening bell on Tuesday?
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken... 
Via Benzinga
AI Is Driving Healthtech Investments To New Heights, But Watch These 3 Overlooked Areas
 
Via Benzinga
Topics Artificial Intelligence
Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Looms
The pharma company is advancing a third late-stage study of its experimental Alzheimer’s drug trontinemab, which uses brain shuttle technology to bypass the blood-brain barrier and clear amyloid... 
Via Stocktwits
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in treatment as well. 
Via The Motley Fool
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. 
Via Benzinga
Topics Artificial Intelligence ETFs
5 Dividend Stocks to Hold for the Next 20 Years
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them! 
Via The Motley Fool
Biotech Is Booming, and This Undervalued REIT Stands to Gain
Via The Motley Fool
Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China
More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the American market. 
Via Benzinga
Topics Law Enforcement Supply Chain
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon. 
Via Benzinga
Topics Economy Government World Trade
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline. 
Via Benzinga
A New Obesity Contender From China Targeting Same Receptors As Eli Lilly's Blockbuster
 
Via Benzinga
The 3 Things That Matter for Eli Lilly Now
Via The Motley Fool
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside 
Via MarketBeat
Topics Artificial Intelligence
Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs
 
Via Benzinga
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
2 Vanguard ETFs That Can Turn $400 per Month Into Over $1.7 Million
Exchange-traded funds (ETFs) can be a lucrative source of wealth for patient investors. 
Via The Motley Fool
Topics ETFs
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.